Pediatric thrombosis: application of dalteparin for treatment and prevention
https://doi.org/10.17650/2311-1267-2015-1-61-65
Abstract
The analysis of the results of dalteparin sodium (Fragmin®) application for the prevention and treatment of thrombosis of various biodisposition in 62 children has been given. The average relative dose depending on the age of the patient, the effectiveness of application and the drug, s safety; the need to select individually controlled doses has been evaluated.
About the Authors
P. V. Svirin
Morozov Children's Hospital;
N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia
Russian Federation
Russian Federation
1/9 4 th Dobryninskiy Per., Moscow, 119049, Russia;
1 Ostrovityanova St., Moscow, 117997, Russia
L. E. Larina
N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia
Russian Federation
1 Ostrovityanova St., Moscow, 117997, Russia
Russian Federation
1 Ostrovityanova St., Moscow, 117997, Russia
P. A. Zharkov
Federal Research Center of Pediatric Hematology, Oncology and Immunology named after Dmitriy Rogachev, Ministry of Health of Russia
Russian Federation
1 Samory Mashela St., Moscow, 117198, Russia
Russian Federation
1 Samory Mashela St., Moscow, 117198, Russia
A. A. Kazankova
Morozov Children, s Hospital
Russian Federation
1/9 4 th Dobryninskiy Per., Moscow, 119049, Russia
Russian Federation
1/9 4 th Dobryninskiy Per., Moscow, 119049, Russia
V. Yu. Petrov
Morozov Children, s Hospital
Russian Federation
1/9 4 th Dobryninskiy Per., Moscow, 119049, Russia
Russian Federation
1/9 4 th Dobryninskiy Per., Moscow, 119049, Russia
I. N. Lavrentyeva
Morozov Children, s Hospital
Russian Federation
1/9 4 th Dobryninskiy Per., Moscow, 119049, Russia
Russian Federation
1/9 4 th Dobryninskiy Per., Moscow, 119049, Russia
References
1. Fisher T. Four Cases of Primary Thrombosis of Cerebral Veins and Sinuses in Children. Br Med J 1901;2(2114):9–12.
2. Andrew M. Developmental hemostasis: relevance to thromboembolic complications in pediatric patients. Thromb Haemost 1995;74(1):415–25.
3. Andrew M., Vegh P., Johnston M. et al. Maturation of the hemostatic system during childhood. Blood 1992;80(8):1998–2005.
4. Nowak-Gottl U., Kosch A., Schlegel N. Thromboembolism in newborns, infants and children. Thromb Haemost 2001;86(1):464–74.
5. Nowak-Gottl U., Kurnik K., Krumpel A., Stoll M. Thrombophilia in the young. Hamostaseologie 2008;28(1–2):16–20.
6. Monagle P., Chan A.K., Goldenberg N.A. et al. Antithrombotic Therapy in Neonates and Children: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012;141: e737S–e801.
7. Bidlingmaier С., Kenet G., Kurnik K. et al. Safety and efficacy of low molecular weight heparins in children: a systematic review of the literature and meta-analysis of single-arm studies. Semin Thromb Hemost 2011;37(7):814–25.
8. Pineo G.F., Hull R.D. Dalteparin sodium. Expert Opin Pharmacother 2001;2(8): 1325–37.
9. Massicotte P., Adams M., Marzinotto V. et al. Low-molecular-weight heparin in pediatric patients with thrombotic disease: a dose finding study. J Pediatr 1996;128(3):313–8.
10. Punzalan R.C., Hillery C.A., Montgomery R.R. et al. Low-molecularweight heparin in thrombotic disease in children and adolescents. J Pediatr Hematol Oncol 2000;22(2):137–42.
11. Massicotte P., Julian J.A., Marzinotto V. et al. Dose-finding and pharmacokinetic profiles of prophylactic doses of a low molecular weight heparin (reviparin-sodium) in pediatric patients. Thromb Res 2003;109(2–3):93–9.
12. Laporte S., Mismetti P., Piquet P. et al. Population pharmacokinetic of nadroparin calcium (Fraxiparine) in children hospitalised for open heart surgery. Eur J Pharm Sci 1999;8(2):119–25.
13. Kuhle S., Massicotte P., Dinyari M. et al. Dose-finding and pharmacokinetics of therapeutic doses of tinzaparin in pediatric patients with thromboembolic events. Thromb Haemost 2005;94(6):1164–71.
14. Trame M.N., Mitchell L., Krumpel A. et al. Population pharmacokinetics of enoxaparin in infants, children and adolescents during secondary thromboembolic prophylaxis: a cohort study. J Thromb Haemost 2010;8(9):1950–8.
15. O'Brien S.H., Kulkarni R., Wallace A. et al. Multicenter dose-finding and efficacy and safety outcomes in neonates and children treated with dalteparin for acute venous thromboembolism. J Thromb Haemost 2014;12(11):1822–5.
16. Nohe N., Flemmer A., Rumler R. et al. The low molecular weight heparin dalteparin for prophylaxis and therapy of thrombosis in childhood: a report on 48 cases. Eur J Pediatr 1999;158(Suppl 3):134–9.
17. Inamo Y., Saito K., Hasegawa M. et al. Effect of dalteparin, a low-molecular-weight heparin, as adjunctive therapy in patients with Kawasaki disease: a retrospective study. BMC Pediatr 2014;14:27.
18. Goldenberg N.A., Jacobson L., Hathaway H. et al. Anti-Xa stability of diluted dalteparin for pediatric use. Ann Pharmacother 2008;42(4):511–5.
Review
For citations:
Svirin P.V., Larina L.E., Zharkov P.A., Kazankova A.A., Petrov V.Yu., Lavrentyeva I.N. Pediatric thrombosis: application of dalteparin for treatment and prevention. Russian Journal of Pediatric Hematology and Oncology. 2015;2(1):61-65. (In Russ.) https://doi.org/10.17650/2311-1267-2015-1-61-65
Views:
1152
Email this article 